Skip to content
★ Sign in to follow
HO

Hans Olov Sören Olsson

IRLAB Therapeutics
Total declarations
5
Company
1
▲ Purchases (5 ops.)
€205k
▼ Sales (0 ops.)
—

Latest filing published 08 Oct 2018 for IRLAB Therapeutics, €64k.

Filing timeline

BuySale
Hans Olov Sören Olsson

Insider track record

Disclosed buys
5
Disclosed sells
0
Signal history

Closed purchases

Market purchases
5

Not enough history yet: 0 closed purchases, at least 2 are needed.

Purchases by company

Hans Olov Sören Olsson: trading record in brief

Hans Olov Sören Olsson is a declared insider of IRLAB Therapeutics, with filings sourced from Finansinspektionen. Between 17 May 2017 and 5 October 2018, the trades on record add up to 5 filings.

No open-market sale appears; the market trades are 5 purchases worth €205k. A purchase on the market is a deliberate choice to commit personal money, which is why it draws more attention than a grant. So far in 2018, the count stands at 2 purchases and no sales.

The median purchase comes to €52k. 5 out of 5 purchases came within 30 days of a purchase by at least one other insider of the same company. Purchases made close together by different insiders form what is called a cluster.

The record was last updated on 8 October 2018 with an open-market purchase (€64k) in IRLAB Therapeutics. The median gap between a trade and its publication by Finansinspektionen is 2 days. The regulation allows three business days to notify a trade (MAR article 19). This summary is built from Finansinspektionen disclosures alone and does not predict where the share price will go.

Companies and markets linked to Hans Olov Sören Olsson

Open company profiles for insider transactions, fundamentals and analyst consensus when available.

Declarations5 total
  • ▲
    Styrelseledamot/suppleantExecutivesIRLAB Therapeutics
    672,000 SEK22FI-SE
    2,000 shares@ SEK 336.0031.5% of flowAktieISIN SE0009242225FI:csv-46d64430816cbfe21cbc
    Canonical exit: 3 Jan 2019 (T+90)
  • ▲
    Styrelseledamot/suppleantExecutivesIRLAB Therapeutics
    696,252 SEK22FI-SE
    5,486 shares@ SEK 126.914334.5% of flowISIN SE0009242225FI:csv-109a33ce900fb9e51c72
    Canonical exit: 24 Apr 2018 (T+90)
  • ▲
    StyrelseledamotExecutivesIRLAB Therapeutics
    506,300 SEK22FI-SE
    8,300 shares@ SEK 61.0025.4% of flowISIN SE0009242225FI:csv-66670368ea9d3336e9ea
    Canonical exit: 22 Aug 2017 (T+90)
  • ▲
    StyrelseledamotExecutivesIRLAB Therapeutics
    103,700 SEK20FI-SE
    1,700 shares@ SEK 61.005.2% of flowISIN SE0009242225FI:csv-d509cdbfc15d309e7822
    Canonical exit: 22 Aug 2017 (T+90)
  • ▲
    Styrelseledamot/suppleantExecutivesIRLAB Therapeutics
    67,671 SEK19FI-SE
    1,314 shares@ SEK 51.503.4% of flowISIN SE0009242225FI:csv-a4a1ca62d179620220f9
    Canonical exit: 15 Aug 2017 (T+90)

5 of 5 declarations